The University of the Sunshine Coast will soon begin a phase one clinical trial of a potential new nasal spray vaccine for COVID-19.
UniSC Clinical Trials will conduct the study, sponsored by Netherlands-based company Intravacc, at its Sippy Downs centre at the Sunshine Coast.
At present, all approved vaccines for COVID-19 are administered by injection into the upper arm. The trial vaccine is administered into the nasal passage, similar to an allergy spray.
UniSC Clinical Trials Principal Investigator Dr Rob Scott, who will oversee the trial, said it would investigate how safe the nasal spray was as a vaccine and how well it worked in eliciting an immune response.
“This is an exciting evolution in vaccines by targeting the virus where it enters the body, by spraying the vaccine into the nasal passage,” Dr Scott said.
“This technology could allow for quicker and safer distribution as it’s easier to transport and store than the average injectable vaccine.”
Lead Clinical Research Coordinator James Donkin said healthy volunteers, aged between 18 and 55, who could commit to up to eight in-person visits and three phone calls for a period of up to 6 months, were being sought for the trial.
“Approximately 36 participants will be enrolled in the study, and will be reimbursed for their time,” he said.
For more information or to register interest in the study, go to www.usc.edu.au/trials
Related articles
Clinical trial of asthma injection that aims to reduce airway inflammation
9 OctUniSC Clinical Trials is investigating an injectable antibody therapy designed to reduce inflammation that causes asthma.
Trial of disease-modifying treatment for early stages of Alzheimer’s disease
3 OctA potential new treatment that could improve cognition and memory in patients with mild to moderate dementia due to Alzheimer’s disease is being investigated by the University of Sunshine Coast.
Focus on healthier people and planet proves winning formula for UniSC
30 AugFrom a ‘game-changing’ koala chlamydia vaccine to a trial of a needle-free flu vaccine, the University of the Sunshine Coast’s success in research and bioinnovation has been recognised in the Life Sciences Queensland GENE Awards.
Media enquiries: Please contact the Media Team media@usc.edu.au